Story excerpt provided by Cincinnati Business Courier.
Written by Lisa Benson.
Assurex Health and a partner in Canada landed a $6 million grant to conduct a genetic testing clinical trial on patients with depression or schizophrenia.
The funds come from Genome Canada and will go to both Assurex and Canada’s Centre for Addiction and Mental Health. According to a news release, the project will be the first clinical trial to evaluate Canadian patients using Assurex’s GeneSight test. The test examines an individual’s DNA to determine the best medication to treat depression, anxiety, ADHD, bipolar disorder, schizophrenia or chronic pain.
Click here to read the complete article.
Originally published October 17, 2014.